The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
Samuel Joseph Paul MalkinDavide CarvalhoCatarina CostaVasco CondeBarnaby HuntPublished in: Diabetology & metabolic syndrome (2022)
Based on a willingness-to-pay threshold of EUR 30,000 per QALY gained, oral semaglutide 14 mg was considered cost-effective versus empagliflozin 25 mg and dulaglutide 1.5 mg for the treatment of type 2 diabetes in Portugal.
Keyphrases